Literature DB >> 20112369

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

Karl Sotlar1, Sema Colak, Anja Bache, Sabina Berezowska, Manuela Krokowski, Burkhard Bültmann, Peter Valent, Hans-Peter Horny.   

Abstract

In a substantial number of patients with systemic mastocytosis (SM), an associated clonal haematological non-mast cell lineage disease (AHNMD) is detectable. Although most of these patients display KIT mutations, especially KIT(D816V), little is known about their exact frequency and their distribution in AHNMD subtypes. We examined 48 patients with SM-AHNMD for the presence of mutant KIT in the SM and AHNMD components of the disease. Mast cells and AHNMD cells were obtained from immunostained bone marrow sections by laser microdissection and examined by melting point analysis of nested-PCR products. KIT(D816V) was found in AHNMD cells in the vast majority of patients with SM-chronic myelomonocytic leukaemia (CMML, 89%). Unexpectedly, KIT(D816V) was far less frequently detectable in AHNMD cells in patients with SM-myeloproliferative neoplasm (MPN, 20%) and SM-acute myeloid leukaemia (AML, 30%). None of the patients with lymphoproliferative AHNMDs displayed KIT codon 816 mutations in AHNMD cells (0/8). In FIP1L1/PDGFRA-positive chronic eosinophilic leukaemia (CEL), neither the SM nor the CEL component of the disease exhibited the KIT mutation. Our findings demonstrate that KIT codon 816 mutations are variably present in AHNMD cells in patients with SM-AHNMD, depending on the subtype of AHNMD. The high frequency of KIT(D816V) in neoplastic mast cells and leukaemic myelomonocytic cells in SM-CMML may point to a common precursor in these patients, and may have implications for the biology of the disease and the development of KIT-targeting therapies. Copyright (c) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112369     DOI: 10.1002/path.2677

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  40 in total

1.  The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD).

Authors:  Peter Valent; Michel Arock; Cem Akin; Wolfgang R Sperr; Andreas Reiter; Karl Sotlar; Karin Hartmann; Tracy I George; Knut Brockow; Hanneke C Kluin-Nelemans; Jason Gotlib; Dean D Metcalfe; Hans-Peter Horny
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

2.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Authors:  M Jawhar; J Schwaab; S Schnittger; M Meggendorfer; M Pfirrmann; K Sotlar; H-P Horny; G Metzgeroth; S Kluger; N Naumann; C Haferlach; T Haferlach; P Valent; W-K Hofmann; A Fabarius; N C P Cross; A Reiter
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

Review 3.  The new tool "KIT" in advanced systemic mastocytosis.

Authors:  William Shomali; Jason Gotlib
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

4.  Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma.

Authors:  Shouying Du; Hooman H Rashidi; Dzung T Le; Thomas J Kipps; H Elizabeth Broome; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2010-04-23

5.  Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.

Authors:  Thomas Kristensen; Hanne Vestergaard; Michael Boe Møller
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

6.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

Review 7.  Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.

Authors:  Britta Haenisch; Markus M Nöthen; Gerhard J Molderings
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

8.  Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.

Authors:  M Jawhar; J Schwaab; D Hausmann; J Clemens; N Naumann; T Henzler; H-P Horny; K Sotlar; S O Schoenberg; N C P Cross; A Fabarius; W-K Hofmann; P Valent; G Metzgeroth; A Reiter
Journal:  Leukemia       Date:  2016-07-15       Impact factor: 11.528

9.  [76-year old patient with suspected but not confirmed "idiopathic myelofibrosis"].

Authors:  C Feld; H Spangenberger; J Böhm; D Meuthen; I Meuthen
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

10.  Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Authors:  Sa A Wang; Lloyd Hutchinson; Guilin Tang; Su S Chen; Patricia M Miron; Yang O Huh; Dan M Jones; Carlos Bueso-Ramos; Srdan Verstovsek; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Am J Hematol       Date:  2013-03       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.